From thoughts posted a few months ago:
I think today's update - specifically for a $1m Revenue upgrade translating into more than a $1.5m increase in EBITDA - a goes a long way to validating CCR management's insistence that margins become temporarily depressed due to on-boarding expenses, and that once the on-boarding process is completed, those costs get backed out.
Which means that the current P&L, which also reflects embedded on-boarding costs, is also pregnant with a few pleasant surprises in the future.
So even though management had been at great pains to explain this dynamic, the market's predilection for focusing only on the very short-term meant that it had some time ago totally tuned out to management's justification for the seemingly-sluggish operating leverage.
I expect today's update will go some distance to getting the market to now think:
"Gee. Actually, it looks like the company's executives weren't making it up after all."
.
- Forums
- ASX - By Stock
- CCR
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-5
Featured News
Add CCR (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.8M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 352 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 15221 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 352 | 0.285 |
2 | 102000 | 0.280 |
1 | 92500 | 0.275 |
2 | 39025 | 0.270 |
7 | 103834 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 15221 | 1 |
0.295 | 18727 | 2 |
0.300 | 44209 | 3 |
0.305 | 76315 | 2 |
0.310 | 218755 | 2 |
Last trade - 16.12pm 24/09/2024 (20 minute delay) ? |
Featured News
CCR (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online